Cargando…
Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
Etanercept and infliximab are novel biological agents targeted against tumour necrosis factor alpha (TNFalpha), a key cytokine in the pathogenesis of rheumatoid arthritis (RA). We report the results of their use over a two year period in 94 patients with severe inflammatory arthritis. Eighty-eight a...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Ulster Medical Society
2002
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2475308/ https://www.ncbi.nlm.nih.gov/pubmed/12513005 |